MoonLake Immunotherapeutics

NASDAQ:MLTX

50.67 (USD) • At close November 7, 2024
Bedrijfsnaam MoonLake Immunotherapeutics
Symbool MLTX
Munteenheid USD
Prijs 50.67
Beurswaarde 3,186,565,362
Dividendpercentage 0%
52-weken bereik 35.53 - 64.98
Industrie Biotechnology
Sector Healthcare
CEO Dr. Jorge Santos da Silva
Website https://www.moonlaketx.com

An error occurred while fetching data.

Over MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or radiographic axial spondyloarthritis. MoonLake Immunotherapeutics was founded in 2021

Vergelijkbare Aandelen

Marinus Pharmaceuticals, Inc. logo

Marinus Pharmaceuticals, Inc.

MRNS

0.359 USD

Pliant Therapeutics, Inc. logo

Pliant Therapeutics, Inc.

PLRX

15.19 USD

DermTech, Inc. logo

DermTech, Inc.

DMTK

0.094 USD

Immunic, Inc. logo

Immunic, Inc.

IMUX

1.18 USD

Kronos Bio, Inc. logo

Kronos Bio, Inc.

KRON

0.9 USD

Personalis, Inc. logo

Personalis, Inc.

PSNL

4.32 USD

Sanara MedTech Inc. logo

Sanara MedTech Inc.

SMTI

33.91 USD

Lyra Therapeutics, Inc. logo

Lyra Therapeutics, Inc.

LYRA

0.265 USD

Tactile Systems Technology, Inc. logo

Tactile Systems Technology, Inc.

TCMD

15.255 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)